Triple Negative Breast Cancer, "I Won't Back Down!": 20th Annual Komen Race for the Cure 2013, Toledo OH.

What is TNBC

WHAT IS TRIPLE NEGATIVE BREAST CANCER?

Just in recent years, Triple Negative Breast Cancer (TNBC) has sparked interest in the news where instead of calling the tumor as ER-negative, PR-negative, and HER2-negative; researchers began using the shorthand term, "Triple Negative," dubbed the "new type" of breast cancer. Being Triple Negative, you don't have a targeted therapy and your only treatment option is chemotherapy.

Triple Negative Breast Cancer is seen in about 15% of all breast cancers. TNBC is a very aggressive cancer that tends to strike younger women, pre-menopause, especially among African-American women and women who have BRCA1 mutations. The tumor tends to be fast growing and is less likely to show up on an annual mammogram. TNBC is more likely to metastasis early on; has a high rate of recurrence in the first 2-3 years from diagnosis and has a poorer prognosis than other types of breast cancer due to lack of specific, targeted treatment for TNBC.

Saturday, October 26, 2013

20th Annual Komen Race for the Cure 2013, Toledo OH.

17, 000 participants in this year's 20th Anniversary Race for the Cure of Northwest, Ohio on September 29, 2013. This is the biggest event in Toledo every year raising more than $1 million with 75% of funds remains in Northwest Ohio to help provide education, screening and support services. In support of my "Pink Sisters" whom I met during this journey, TNBC sisters that I've known to battle to the end and to those that are still fighting fiercely, I continue to fight beside you all and in your honor.

As of 2013, Susan G. Komen has invested more than $74 million in over 100 research grants focused on triple negative breast cancer since it was first identified as a distinct type of breast cancer in 2006.